
BioNTech SE (BNTX) Stock Forecast & Price Target
BioNTech SE (BNTX) Analyst Ratings
Bulls say
BioNTech concluded the third quarter of 2025 with approximately €16.7 billion in cash, cash equivalents, marketable securities, and trade receivables, reflecting a solid liquidity position that supports ongoing research and development efforts. The company's diverse oncology pipeline, which includes mRNA-based drugs and various classes of immunotherapies, positions it favorably for potential therapeutic advancements and market expansions. Additionally, encouraging developments in the clinical evaluation of BNT323 and the improved immune responses demonstrated by their adapted COVID-19 vaccine enhance the company's outlook for sustained growth.
Bears say
The financial outlook for BioNTech is significantly challenged by various risks, including unfavorable data from multiple clinical programs and slower market adoption of their products. In the third quarter of 2025, the company reported a net loss per diluted share of €0.12, with a projected full-year loss of €3.99, indicating ongoing financial difficulties. Additionally, the changing dynamics in the COVID-19 vaccine market, particularly due to a more restrictive regulatory environment in the U.S., may detract investor focus from the company's oncology initiatives.
This aggregate rating is based on analysts' research of BioNTech SE and is not a guaranteed prediction by Public.com or investment advice.
BioNTech SE (BNTX) Analyst Forecast & Price Prediction
Start investing in BioNTech SE (BNTX)
Order type
Buy in
Order amount
Est. shares
0 shares